KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

December 7, 2023 |

8 min read

KalVista Pharmaceuticals, Inc . today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.

- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial -

- Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 -

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.

“We are in the process of completing the KONFIDENT trial and we look forward to advancing sebetralstat for a NDA submission in the first half of 2024,” said Andrew Crockett, Chief Executive Officer of KalVista. “As we plan on several regulatory filings in the coming year, we are also continuing to build out our commercial organization in order to support a rapid launch upon FDA approval.”

Second Fiscal Quarter and Recent Business Highlights:

Achieved the targeted number of on-treatment attacks required to complete the phase 3 KONFIDENT trial. Topline data readout is expected in early 2024, remaining on track for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2024. The Company also expects to file for approval in the European Union and Japan later in 2024
Received Orphan Drug Status (ODS) approval from Switzerland for sebetralstat, allowing for shorter review time, priority authorization, and 15 years market protection and exclusivity
Presented real-world patient data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology discussing compliance challenges of currently available parenteral on-demand HAE treatments and evidence of the global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH)
Conducted fireside chats at the Cantor Global Healthcare Conference, Stifel 2023 Healthcare Conference, and Jefferies London Healthcare Conference
Reported data at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference characterizing HAE attacks in patients receiving long-term prophylaxis (LTP)

Second Fiscal Quarter Financial Results:

Revenue: No revenue was recognized for the three months ended October 31, 2023, or October 31, 2022.

R&D Expenses: Research and development expenses were $19.1 million for the three months ended October 31, 2023, compared to $18.1 million for the same period in the prior fiscal year. The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials.

G&A Expenses: General and administrative expenses were $10.7 million for the three months ended October 31, 2023, compared to $7.8 million for the same period in the prior fiscal year. The increase in G&A expenses was primarily due to increases in employee-related expenses, commercial strategy and supply chain expenses.

Net Loss: Net loss was $27.7 million, or $(0.80) per weighted average basic and diluted share, for the three months ended October 31, 2023, compared to net loss of $22.3 million, or $(0.90) per weighted average basic and diluted share for the same period in the prior fiscal year. The increase in net loss primarily resulted from the increase in operating expenses, primarily research and development.

Cash Position: Cash, cash equivalents and marketable securities were $103.2 million as of October 31, 2023, compared to $149.4 million as of April 30, 2023. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE and anticipates providing data from the phase 3 KONFIDENT clinical trial in early 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)

	October 31,			April 30,
		2023			2023
Assets
Current assets:
Cash and cash equivalents	$	57,666		$	56,238
Marketable securities		45,506			93,137
Research and development tax credit receivable		19,976			16,568
Prepaid expenses and other current assets		5,458			6,383
Total current assets		128,606			172,326
Property and equipment, net		2,502			2,948
Right of use assets		7,298			7,822
Other assets		337			106
Total assets	$	138,743		$	183,202
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	4,896		$	4,817
Accrued expenses		11,707			9,128
Lease liability - current portion		1,148			1,087
Total current liabilities		17,751			15,032
Long-term liabilities:
Lease liability - net of current portion		6,546			7,145
Total long-term liabilities		6,546			7,145
Stockholders’ equity:
Common stock, $0.001 par value		34			34
Additional paid-in capital		513,926			507,133
Accumulated deficit		(396,049	)		(343,082	)
Accumulated other comprehensive loss		(3,465	)		(3,060	)
Total stockholders’ equity		114,446			161,025
Total liabilities and stockholders’ equity	$	138,743		$	183,202

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)


	Three Months Ended						Six Months Ended
	October 31,						October 31,
		2023			2022			2023			2022

Revenue	$	—		$	—		$	—		$	—
Operating expenses:
Research and development		19,089			18,077			38,396			36,262
General and administrative		10,657			7,806			20,443			15,936
Total operating expenses		29,746			25,883			58,839			52,198
Operating loss		(29,746	)		(25,883	)		(58,839	)		(52,198	)

Other income:
Interest income		776			449			1,699			691
Foreign currency exchange rate (loss) gain		(1,299	)		(317	)		(843	)		(834	)
Other income		2,619			3,494			5,016			7,042
Total other income		2,096			3,626			5,872			6,899
Net loss	$	(27,650	)	$	(22,257	)	$	(52,967	)	$	(45,299	)

Net loss per share, basic and diluted	$	(0.80	)	$	(0.90	)	$	(1.54	)	$	(1.84	)

Weighted average common shares outstanding, basic and diluted		34,565,955			24,595,039			34,490,090			24,576,327

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)

	Six Months Ended
	October 31,
		2023			2022

Cash flows from operating activities
Net loss	$	(52,967	)	$	(45,299	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		390			331
Stock-based compensation expense		6,461			5,148
Realized loss (gain) from sale of marketable securities		(909	)		85
Non-cash operating lease expense		(13	)		42
Amortization of premium on marketable securities		83			678
Foreign currency exchange loss (gain)		811			(739	)
Changes in operating assets and liabilities:
Research and development tax credit receivable		(4,109	)		(7,137	)
Prepaid expenses and other current assets		761			3,650
Accounts payable		163			(81	)
Accrued expenses		2,774			(14	)
Net cash used in operating activities		(46,555	)		(43,336	)

Cash flows from investing activities
Purchases of marketable securities		(29,537	)		(10,102	)
Sales and maturities of marketable securities		77,917			61,356
Acquisition of property and equipment		(8	)		(1,112	)
Website development costs		(203	)		—
Net cash provided by investing activities		48,169			50,142

Cash flows from financing activities
Issuance of common stock from equity incentive plans		332			336
Net cash provided by financing activities		332			336
Effect of exchange rate changes on cash and cash equivalents		(518	)		711
Net (decrease) increase in cash and cash equivalents		1,428			7,853
Cash and cash equivalents at beginning of period		56,238			30,732
Cash and cash equivalents at end of period	$	57,666		$	38,585